Anticalins: inhalable biologicals for severe asthma [ 2015 - 2017 ]

Research Grant

Researchers: Prof Gary Anderson (Principal investigator) ,  A/Pr Louis Irving ,  A/Pr Steven Bozinovski ,  Prof Ross Vlahos

Brief description This grant aims to develop a new class of medicines called 'anticalins'. Anticalins behave like a successful class of medicines called monoclonal antibodies (mAbs). MAbs are too fragile and large to be inhaled to treat lung disease but anticalins are small and robust. We will be developing an anticalin (PRS-060) which blocks damaging immune reactions in severe asthma. By inhaling PRS-060 we hope to make a new and clinically useful medicine for a common form of poorly-controlled severe asthma.

Funding Amount $AUD 577,933.14

Funding Scheme Development Grants

Notes Development Grant